País: Canadá
Língua: inglês
Origem: Health Canada
CANDESARTAN CILEXETIL
ANGITA PHARMA INC.
C09CA06
CANDESARTAN
8MG
TABLET
CANDESARTAN CILEXETIL 8MG
ORAL
15G/50G
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0135220002; AHFS:
APPROVED
2020-06-22
1 PRODUCT MONOGRAPH Pr AG-Candesartan Tablets Candesartan Cilexetil Tablets 8 mg, 16 mg and 32 mg Angiotensin II AT 1 Receptor Blocker Date of Revision: June 19, 2020 Submission Control No.: 239327 J4B 5H3 Boucherville , Québec 1310 rue Nobel Angita Pharma Inc. 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ...........................................................3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ......................................................................................................... 4 WARNINGS AND PRECAUTIONS ........................................................................................ 4 ADVERSE RE ACT IONS .................................................................................................. 8 DRUG INTERACTIONS ........................................................................................................ 14 DOS AGE AND AD MINISTRAT IO N......................................................................... 18 O V E RD O SA GE .......................................................................................... 21 ACTION AND CLINICAL PHARMAC OLOGY ................................................... 21 STORAGE AND STABILITY ................................................................................................ 23 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................. 23 PART II: SCIENTIFIC INFORMATION .................................................................................25 PHARMACEUTICAL INFORMATION 25 CLINICAL TRIALS .......................................................................................................... 26 DET AIL ED PHARMACO LOG Y ................................................................................. 30 TO XI COL O G Y ................................ Leia o documento completo